Abstract:Context: Visceral pain is a leading symptom for patients with irritable bowel syndrome (IBS) that affects 10% - 20 % of the world population. Conventional pharmacological treatments to manage IBS-related visceral pain is unsatisfactory. Recently, medications have emerged to treat IBS patients by targeting the gastrointestinal (GI) tract and peripheral nerves to alleviate visceral pain while avoiding adverse effects on the central nervous system (CNS). Several investigational drugs for IBS also target the periphery with minimal CNS effects. Evidence of acquisition: In this paper, reputable internet databases from 1960 - 2016 were searched including Pubmed and ClinicalTrials.org, and 97 original articles analyzed. Search was performed based on the following keywords and combinations: irritable bowel syndrome, clinical trial, pain, visceral pain, narcotics, opioid, chloride channel, neuropathy, primary afferent, intestine, microbiota, gut barrier, inflammation, diarrhea, constipation, serotonin, visceral hypersensitivity, nociceptor, sensitization, hyperalgesia. Results: Certain conventional pain managing drugs do not effectively improve IBS symptoms, including NSAIDs, acetaminophen, aspirin, and various narcotics. Anxiolytic and antidepressant drugs (Benzodiazepines, TCAs, SSRI and SNRI) can attenuate pain in IBS patients with relevant comorbidities. Clonidine, gabapentin and pregabalin can moderately improve IBS symptoms. Lubiprostone relieves constipation predominant IBS (IBS-C) while loperamide improves diarrhea predominant IBS (IBS-D). Alosetron, granisetron and ondansetron can generally treat pain in IBS-D patients, of which alosetron needs to be used with caution due to cardiovascular toxicity. The optimal drugs for managing pain in IBS-D and IBS-C appear to be eluxadoline and linaclotide, respectively, both of which target peripheral GI tract. Conclusions: Conventional pain managing drugs are in general not suitable for treating IBS pain. Medications that target the GI tract and peripheral nerves have better therapeutic profiles by limiting adverse CNS effects.

New and Investigational Agents for Irritable Bowel Syndrome

New drugs in the management of the irritable bowel syndrome

Irritable bowel syndrome: recent and novel therapeutic approaches

Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs

New developments in the treatment of irritable bowel syndrome

Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea

Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches

Phytochemistry, ethnopharmacology and novel formulations based approaches for the treatment of irritable bowel syndrome: a comprehensive review

Current and novel therapeutic options for irritable bowel syndrome management

Current Recommendations and Evidence

Current and future pharmacotherapies for the management of constipation-predominant irritable bowel syndrome

Irritable Bowel Syndrome: A Review and Update

Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M)

Pharmacological treatment of irritable bowel syndrome--from concept to sales

Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article

[The proven and the new in the pharmacotherapy of irritable bowel syndrome]

Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what's new?

Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview

New Insights into the Irritable Bowel Syndrome

Targeting diarrhea-predominant irritable bowel syndrome: hopes or hypes?

Inflammatory Bowel Sugar Disease: A Pause From New Pharmacological Agents and an Embrace of Natural Therapy